gatifloxacin has been researched along with Health Care Associated Infection in 10 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since 2002, an epidemic of Clostridium difficile infections has occurred in southern Quebec, Canada." | 1.35 | Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. ( Béliveau, C; Labbé, AC; Laverdière, M; Louie, T; Maccannell, D; Pépin, J; Poirier, L; Savoie, M, 2008) |
| "Levofloxacin was added to the formulary in 1999, and gatifloxacin was substituted for levofloxacin in 2001." | 1.33 | Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus. ( Bosso, JA; Mauldin, PD, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (90.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mendes, RE | 1 |
| Castanheira, M | 1 |
| Toleman, MA | 1 |
| Sader, HS | 1 |
| Jones, RN | 1 |
| Walsh, TR | 1 |
| Quiroga, MP | 1 |
| Andres, P | 1 |
| Petroni, A | 1 |
| Soler Bistué, AJ | 1 |
| Guerriero, L | 1 |
| Vargas, LJ | 1 |
| Zorreguieta, A | 1 |
| Tokumoto, M | 1 |
| Quiroga, C | 1 |
| Tolmasky, ME | 1 |
| Galas, M | 1 |
| Centrón, D | 1 |
| Labbé, AC | 1 |
| Poirier, L | 1 |
| Maccannell, D | 1 |
| Louie, T | 1 |
| Savoie, M | 1 |
| Béliveau, C | 1 |
| Laverdière, M | 1 |
| Pépin, J | 1 |
| Jump, RL | 1 |
| Riggs, MM | 1 |
| Sethi, AK | 1 |
| Pultz, MJ | 1 |
| Ellis-Reid, T | 1 |
| Riebel, W | 1 |
| Gerding, DN | 1 |
| Salata, RA | 1 |
| Donskey, CJ | 1 |
| Gaynes, R | 1 |
| Rimland, D | 1 |
| Killum, E | 1 |
| Lowery, HK | 1 |
| Johnson, TM | 1 |
| Killgore, G | 1 |
| Tenover, FC | 1 |
| Mohr, J | 1 |
| Bosso, JA | 1 |
| Mauldin, PD | 1 |
| Sirvent, E | 1 |
| Ruiz, M | 1 |
| Rodríguez, JC | 1 |
| Royo, G | 1 |
| Cohn, ML | 1 |
| Waites, KB | 1 |
| Leroi, MJ | 1 |
| Siarakas, S | 1 |
| Gottlieb, T | 1 |
10 other studies available for gatifloxacin and Health Care Associated Infection
| Article | Year |
|---|---|
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
Topics: Acinetobacter; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Base Sequence; Brazil; C | 2007 |
Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
Topics: Alleles; Amino Acid Sequence; Argentina; Bacterial Proteins; Base Sequence; beta-Lactamases; Cross I | 2007 |
Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.
Topics: Adult; Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Community-Acqu | 2008 |
Multihospital outbreak of Clostridium difficile infection, Cleveland, Ohio, USA.
Topics: Anti-Infective Agents; Aza Compounds; Clostridioides difficile; Clostridium Infections; Cross Infect | 2010 |
Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use.
Topics: Case-Control Studies; Clostridioides difficile; Clostridium Infections; Cross Infection; Diarrhea; D | 2004 |
Outbreak of Clostridium difficile infection and gatifloxacin use in a long-term care facility.
Topics: Anti-Infective Agents; Clostridioides difficile; Cross Infection; Enterocolitis, Pseudomembranous; F | 2004 |
Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Escherichia coli; Fluo | 2006 |
[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Dr | 2006 |
Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies.
Topics: Anti-Infective Agents; Cross Infection; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infe | 2001 |
E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid.
Topics: Acetamides; Anti-Infective Agents; Aza Compounds; Clostridioides difficile; Clostridium Infections; | 2002 |